+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Astellas

The publisher explores Astellas’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Astellas is forecast to grow revenue until 2026, at which point flagship product Xtandi will face the loss of patent exclusivity.
  • Key themes - [1] Minimal short-term losses due to termination of sales and distribution agreement for Symbicort as well as decreases in vaccine revenues will be offset by its growing products [2] Astellas’s growth will be determined by new launched and pipeline assets such as Xospata, Evrenzo, and Evenity.
Model updates (31 October 2020)
  • Xtandi forecast adjusted higher due to continued growth in prostate cancer
  • Xospata forecast adjusted higher
  • Celebrex forecast adjusted lower due to generic competition
  • Sujanu forecast adjusted higher due to continued growth
  • AT132 removed from forecast due to multiple patient deaths and clinical hold in ASPIRO trial.
Model updates (31 January 2020)
  • Xospata forecast adjusted higher due to Europe launch
  • Evenity forecast adjusted higher due to launch results
  • Padcev EU and ROW launches expedited
  • Roxadustat name changed to Evrenzo
  • AT132 launch added due to closing of Audentes acquisition.
Model updates (31 October 2019)
  • Xtandi revenue adjusted higher due to non-metastatic castration-resistant prostate cancer prescriptions exceeding forecast in the US
  • Prograf forecast adjusted higher due to lower generic impact in the US
  • Micardis forecast adjusted higher due to generic performance
  • Roxadustat forecast adjusted for approval
  • Symbicort forecast removed due to termination of sales and distribution agreement with KM Biologics
  • Vaccines forecast adjusted lower due to company guidance.
Model updates (14 August 2019)
  • AmBisome forecast adjusted higher due to company guidance
  • Celebrex forecast adjusted higher due to company guidance
  • Cresemba forecast adjusted lower for future patent expiry
  • Mycamine forecast adjusted higher due to company guidance
  • Xtandi forecast adjusted higher due to prostate cancer and overactive bladder treatment approvals
  • Xospata forecast adjusted higher due to launch results
  • Myrbetriq forecast adjusted lower due to company guidance
  • Vesicare forecast adjusted lower due to generic competition
  • Prograf forecast adjusted higher due to company guidance and expansion of clinical adoption in China
  • Evenity forecast adjusted higher due to launch results
  • Enfortumab vedotin forecast added
  • Fezolinetant forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll